Press releases

Bionure and National Multiple Sclerosis Society Enter into a Collaboration to Support the Development of a New Chemical Entity for Optic Neuritis and Multiple Sclerosis
Download pdf


MENLO PARK, CA. January 09, 2015. Bionure, Inc. a California-based late-preclinical drug development company, today announced that it has entered into a Sponsored Research Agreement with the National Multiple Sclerosis Society through Fast Forward, its commercial research subsidiary aimed at accelerating the development of new and improved therapies for MS. Under this agreement, Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable IND filling to support the Phase 1 clinical study in Acute Optic Neuritis (AON). Optic neuritis is often a first sign of multiple sclerosis.

Bionure Inc.’s MS Drug Candidate Shows Positive Results for Myelin Repair in Cell Culture Assay
Download pdf


PALO ALTO, CA. May 27, 2014. Bionure Inc. today announced its drug candidate, BN201, was shown to promote myelination — the cellular process of repairing the protective sheath surrounding nerves that is damaged in people with multiple sclerosis (MS). The pre‐clinical study was conducted in a novel cell culture assay developed by the Myelin Repair Foundation (MRF) and assessed at the Foundation’s Translational Medicine Center under a previously announced collaborative agreement.

The Myelin Repair Foundation Enters First International Partnership with Bionure, Inc.
Download pdf


SARATOGA, CA. October 31, 2013. The Myelin Repair Foundation (MRF) and Bionure, Inc. today entered a collaborative partnership agreement to advance therapeutics development for Multiple Sclerosis (MS). The Foundation’s unique Accelerated Research Collaboration™ (ARC™) model facilitates collaboration between the top MS leaders worldwide to advance promising compounds into the clinic. In this agreement, the Myelin Repair Foundation will work closely with Bionure, Inc. to assess the neuroprotective capabilities that will promote myelin repair of the company’s proprietary MS therapeutic compound, BN201.